All companies
Visit website
Bioverge
OperatingBioverge, Inc.
Biotech · Founded 2017
Bioverge is an investment platform that funds visionary entrepreneurs with the aim of transforming healthcare and bringing science fiction to life.
Valuation cap ⓘ
$25.0M
As of Aug 2023 · from Bioverge Crowd SAFE 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$882,813
Across 2 rounds since 2021
Latest share price
$1.14
Bioverge Stock 1 offering price
Financials
FY2019–FY2024 · from SEC filings · hover any figure for its source$24K
−$161K
2019
$69K
−$433K
2020
$252K
−$592K
2021
$248K
−$406K
2022
$248K
−$406K
2023
$136K
−$431K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$24,047
$68,795
$251,720
$247,786
$247,786
$136,253
Cost of goods sold
$0
$498,618
$26,101
$49,972
$49,972
$26,615
Gross margin
100%
-625%
90%
80%
80%
80%
Net income
-$161,357
-$432,913
-$591,903
-$406,203
-$406,203
-$431,300
Taxes paid
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$266,383
$570,343
$383,999
$243,289
$81,025
$148,876
Accounts receivable
$4,997
$7,034
$0
$0
$0
$0
Total assets
$544,624
$580,219
$751,759
$567,769
$567,769
$845,468
Short-term debt
$123,702
$0
$178,120
$52,668
$224,391
$169,136
Long-term debt
$588,520
$1,584,627
$0
$0
$408,500
$452,518
Total liabilities
$712,222
$1,584,627
$178,120
$52,668
$632,891
$621,654
Other
Headcount
—
2
2
2
—
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$10.7M
post-money
$25.0M
Valuation cap
Bioverge Stock 1
Bioverge Crowd SAFE 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $138K / $1.2MInvestors 251Valuation cap $25M
Raised $744.8K / $1.1MPost-money $10.7M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 3 of 5 annual reports (FY2021–FY2025)
251 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 17 filings on EDGARSource: ManualCIK 0001828649Share price $1.14
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.